GSK and Alamar Biosciences will profile more than 60,000 serum samples using the NULISA proteomic platform to determine whether patients sharing a single clinical diagnosis belong to biologically distinct subgroups. The immune and neurological protein panels span respiratory, liver, kidney, neurological and autoimmune conditions, with results linked to recorded diagnoses, prescribing patterns and clinical outcomes. For longevity, the relevant question is whether circulating protein signatures can predict susceptibility and severity across the lifespan, before clinical disease declares itself.
Key Points
- 60,000 serum samples profiled across five organ-system disease areas
- Immune and neurological panels test for subtypes under single diagnoses
- Protein signatures assessed for susceptibility, severity and drug response
Longevity Analysis
Shared diagnostic labels obscure divergent biology, which is why identical prescriptions produce opposite trajectories in two patients. Measuring circulating immune and neurological proteins across liver, kidney, lung and autoimmune cohorts tests whether the same inflammatory and clearance patterns recur across organs — the question underlying most age-related decline. Resolution at this level shifts intervention from treating a named condition to correcting the specific signal that is misfiring, and from reacting after diagnosis to acting on measurable drift years earlier.
Original published by Longevity.Technology, by Eleanor Garth.